You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Nucala (meplizumab) patient search the internet for nucala patient information on the patient website

Nucala is an asthma medicine used to treat patients aged 6 years and above with a particular type of asthma called severe eosinophilic asthma. It is used with other medicines in patients whose asthma is severe and not well controlled with previous treatments. Nucala contains the active substance mepolizumab.

Safety Information

For further information on Nucala, please see the Nucala patient information leaflet (PIL). This link will take you to the electronic Medicines Compendium website which is a non-GSK website.

Summary of Product Characteristics and Patient Information Leaflet (GB)

Summary of Product Characteristics and Patient Information Leaflet (NI)

Patient information

This page can help you make the most of your treatment, but if you have any questions or concerns just ask your doctor, pharmacist or nurse.
 

I am a patient

Nucala is a registered trademark of the GlaxoSmithKline group of companies

If you experience any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine